Pharmacological inhibition of cyclin dependent kinases causes p53 dependent apoptosis in renal cell carcinoma

Tatsuto Ishimaru, Jasmine Lau, Amy L. Jackson, Jaime F. Modiano, Robert H Weiss

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose We evaluated the effect of roscovitine (Sigma-Aldrich®), a pharmacological inhibitor of cyclin dependent kinase, on renal cell carcinoma cell lines in vitro. Materials and Methods We exposed several renal cell carcinoma cell lines to roscovitine and examined apoptotic signaling pathways using immunoblotting and immunohistochemistry. Results As expected, roscovitine caused dose and time dependent inhibition of cyclin dependent kinase 2 autophosphorylation, and of cyclin dependent kinase mediated Pol II phosphorylation in the ACHN (p53-wt) and 786-O (p53 inactive) renal cell carcinoma cell lines (ATCC®). Roscovitine also induced apoptosis in each cell line within a narrow concentration range (about 10 μg/ml). Apoptosis induction was more efficient in ACHN than in 786-O cells and at least partly due to p53 activity. In ACHN cells roscovitine induced apoptosis was associated with p21 induction, and decreased Akt1, XIAP and phospho-Rb expression. These changes also depended on p53 and were not present (p21) or showed a different dose pattern (Akt1, XIAP and phospho-Rb) in 786-O cells. Partial restoration of roscovitine induced apoptosis in 786-O cells by the Mdm-2 inhibitor nutlin-3 (Sigma-Aldrich) suggests that the inactivating mutation of VHL in these cells and its destabilizing effect on p53 are responsible for the decreased sensitivity to apoptosis. Conclusions Our data extend previous studies documenting the pro-apoptotic effect of roscovitine and to our knowledge show for the first time that this activity is restricted to a narrow dose range in renal cell carcinoma cells and partly depends on p53. Thus, roscovitine is a novel potential chemotherapy in a subset of patients with renal cell carcinoma if a narrow therapeutic window is used. These data also provide insight into the role of VHL mutation and p53 in the renal cell carcinoma response to therapeutic cyclin dependent kinase manipulation.

Original languageEnglish (US)
Pages (from-to)2143-2149
Number of pages7
JournalJournal of Urology
Volume184
Issue number5
DOIs
StatePublished - Nov 2010
Externally publishedYes

Fingerprint

Cyclin-Dependent Kinases
Renal Cell Carcinoma
Pharmacology
Apoptosis
Cell Line
Cyclin-Dependent Kinase 2
Mutation
roscovitine
Immunoblotting
Immunohistochemistry
Phosphorylation
Drug Therapy
Therapeutics

Keywords

  • Apoptosis
  • Carcinoma, renal cell
  • Cyclin-dependent kinases
  • Kidney
  • Roscovitine

ASJC Scopus subject areas

  • Urology
  • Medicine(all)

Cite this

Pharmacological inhibition of cyclin dependent kinases causes p53 dependent apoptosis in renal cell carcinoma. / Ishimaru, Tatsuto; Lau, Jasmine; Jackson, Amy L.; Modiano, Jaime F.; Weiss, Robert H.

In: Journal of Urology, Vol. 184, No. 5, 11.2010, p. 2143-2149.

Research output: Contribution to journalArticle

Ishimaru, Tatsuto ; Lau, Jasmine ; Jackson, Amy L. ; Modiano, Jaime F. ; Weiss, Robert H. / Pharmacological inhibition of cyclin dependent kinases causes p53 dependent apoptosis in renal cell carcinoma. In: Journal of Urology. 2010 ; Vol. 184, No. 5. pp. 2143-2149.
@article{bf9bf03e2b514bb9be0d2f85acbe6154,
title = "Pharmacological inhibition of cyclin dependent kinases causes p53 dependent apoptosis in renal cell carcinoma",
abstract = "Purpose We evaluated the effect of roscovitine (Sigma-Aldrich{\circledR}), a pharmacological inhibitor of cyclin dependent kinase, on renal cell carcinoma cell lines in vitro. Materials and Methods We exposed several renal cell carcinoma cell lines to roscovitine and examined apoptotic signaling pathways using immunoblotting and immunohistochemistry. Results As expected, roscovitine caused dose and time dependent inhibition of cyclin dependent kinase 2 autophosphorylation, and of cyclin dependent kinase mediated Pol II phosphorylation in the ACHN (p53-wt) and 786-O (p53 inactive) renal cell carcinoma cell lines (ATCC{\circledR}). Roscovitine also induced apoptosis in each cell line within a narrow concentration range (about 10 μg/ml). Apoptosis induction was more efficient in ACHN than in 786-O cells and at least partly due to p53 activity. In ACHN cells roscovitine induced apoptosis was associated with p21 induction, and decreased Akt1, XIAP and phospho-Rb expression. These changes also depended on p53 and were not present (p21) or showed a different dose pattern (Akt1, XIAP and phospho-Rb) in 786-O cells. Partial restoration of roscovitine induced apoptosis in 786-O cells by the Mdm-2 inhibitor nutlin-3 (Sigma-Aldrich) suggests that the inactivating mutation of VHL in these cells and its destabilizing effect on p53 are responsible for the decreased sensitivity to apoptosis. Conclusions Our data extend previous studies documenting the pro-apoptotic effect of roscovitine and to our knowledge show for the first time that this activity is restricted to a narrow dose range in renal cell carcinoma cells and partly depends on p53. Thus, roscovitine is a novel potential chemotherapy in a subset of patients with renal cell carcinoma if a narrow therapeutic window is used. These data also provide insight into the role of VHL mutation and p53 in the renal cell carcinoma response to therapeutic cyclin dependent kinase manipulation.",
keywords = "Apoptosis, Carcinoma, renal cell, Cyclin-dependent kinases, Kidney, Roscovitine",
author = "Tatsuto Ishimaru and Jasmine Lau and Jackson, {Amy L.} and Modiano, {Jaime F.} and Weiss, {Robert H}",
year = "2010",
month = "11",
doi = "10.1016/j.juro.2010.06.088",
language = "English (US)",
volume = "184",
pages = "2143--2149",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Pharmacological inhibition of cyclin dependent kinases causes p53 dependent apoptosis in renal cell carcinoma

AU - Ishimaru, Tatsuto

AU - Lau, Jasmine

AU - Jackson, Amy L.

AU - Modiano, Jaime F.

AU - Weiss, Robert H

PY - 2010/11

Y1 - 2010/11

N2 - Purpose We evaluated the effect of roscovitine (Sigma-Aldrich®), a pharmacological inhibitor of cyclin dependent kinase, on renal cell carcinoma cell lines in vitro. Materials and Methods We exposed several renal cell carcinoma cell lines to roscovitine and examined apoptotic signaling pathways using immunoblotting and immunohistochemistry. Results As expected, roscovitine caused dose and time dependent inhibition of cyclin dependent kinase 2 autophosphorylation, and of cyclin dependent kinase mediated Pol II phosphorylation in the ACHN (p53-wt) and 786-O (p53 inactive) renal cell carcinoma cell lines (ATCC®). Roscovitine also induced apoptosis in each cell line within a narrow concentration range (about 10 μg/ml). Apoptosis induction was more efficient in ACHN than in 786-O cells and at least partly due to p53 activity. In ACHN cells roscovitine induced apoptosis was associated with p21 induction, and decreased Akt1, XIAP and phospho-Rb expression. These changes also depended on p53 and were not present (p21) or showed a different dose pattern (Akt1, XIAP and phospho-Rb) in 786-O cells. Partial restoration of roscovitine induced apoptosis in 786-O cells by the Mdm-2 inhibitor nutlin-3 (Sigma-Aldrich) suggests that the inactivating mutation of VHL in these cells and its destabilizing effect on p53 are responsible for the decreased sensitivity to apoptosis. Conclusions Our data extend previous studies documenting the pro-apoptotic effect of roscovitine and to our knowledge show for the first time that this activity is restricted to a narrow dose range in renal cell carcinoma cells and partly depends on p53. Thus, roscovitine is a novel potential chemotherapy in a subset of patients with renal cell carcinoma if a narrow therapeutic window is used. These data also provide insight into the role of VHL mutation and p53 in the renal cell carcinoma response to therapeutic cyclin dependent kinase manipulation.

AB - Purpose We evaluated the effect of roscovitine (Sigma-Aldrich®), a pharmacological inhibitor of cyclin dependent kinase, on renal cell carcinoma cell lines in vitro. Materials and Methods We exposed several renal cell carcinoma cell lines to roscovitine and examined apoptotic signaling pathways using immunoblotting and immunohistochemistry. Results As expected, roscovitine caused dose and time dependent inhibition of cyclin dependent kinase 2 autophosphorylation, and of cyclin dependent kinase mediated Pol II phosphorylation in the ACHN (p53-wt) and 786-O (p53 inactive) renal cell carcinoma cell lines (ATCC®). Roscovitine also induced apoptosis in each cell line within a narrow concentration range (about 10 μg/ml). Apoptosis induction was more efficient in ACHN than in 786-O cells and at least partly due to p53 activity. In ACHN cells roscovitine induced apoptosis was associated with p21 induction, and decreased Akt1, XIAP and phospho-Rb expression. These changes also depended on p53 and were not present (p21) or showed a different dose pattern (Akt1, XIAP and phospho-Rb) in 786-O cells. Partial restoration of roscovitine induced apoptosis in 786-O cells by the Mdm-2 inhibitor nutlin-3 (Sigma-Aldrich) suggests that the inactivating mutation of VHL in these cells and its destabilizing effect on p53 are responsible for the decreased sensitivity to apoptosis. Conclusions Our data extend previous studies documenting the pro-apoptotic effect of roscovitine and to our knowledge show for the first time that this activity is restricted to a narrow dose range in renal cell carcinoma cells and partly depends on p53. Thus, roscovitine is a novel potential chemotherapy in a subset of patients with renal cell carcinoma if a narrow therapeutic window is used. These data also provide insight into the role of VHL mutation and p53 in the renal cell carcinoma response to therapeutic cyclin dependent kinase manipulation.

KW - Apoptosis

KW - Carcinoma, renal cell

KW - Cyclin-dependent kinases

KW - Kidney

KW - Roscovitine

UR - http://www.scopus.com/inward/record.url?scp=77957846979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957846979&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2010.06.088

DO - 10.1016/j.juro.2010.06.088

M3 - Article

C2 - 20850841

AN - SCOPUS:77957846979

VL - 184

SP - 2143

EP - 2149

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -